Consensus LifeMD, Inc.

Stocks

LFMD

US53216B1044

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 02:11:01 23/09/26 am AEST			5-day change	1st Jan Change
3.300 ^USD	+2.33%		-2.79%	-3.08%

07/08	B. Riley Adjusts Price Target on LifeMD to $8 From $10, Maintains Buy Rating	MT
06/08	LifeMD, Inc., Q2 2026 Earnings Call, Aug 05, 2026

Evolution of the Average Target: LifeMD, Inc.

Evolution of the Target Price: LifeMD, Inc.

Changes in Analyst Recommendations: LifeMD, Inc.

9a23cb67d645b0.DTB5IUfkITgzZQn-IIZpQ5jDwekP4wYbj1S3zs5RakY.QWY0YyqUSHkLAjG6RMAid-2SqpNuqHNszDb8iIsoLABECUkSJIBGcUsvYg~22a29449e2e62654ffa95501adc83511

Analysts' recommendations: LifeMD, Inc.

07/08	B. Riley Adjusts Price Target on LifeMD to $8 From $10, Maintains Buy Rating	MT
16/03	Mizuho Upgrades LifeMD to Outperform From Neutral, Adjusts Price Target to $8 From $6	MT
17/01	Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly	RE
06/01	Sector Update: Health Care Stocks Decline Late Afternoon	MT
19/11	B. Riley Adjusts Price Target on LifeMD to $10 From $12, Maintains Buy Rating	MT
08/01/25	KeyBanc Cuts Price Target on LifeMD to $7.50 From $10, Keeps Overweight Rating	MT
04/12/24	Mizuho Initiates LifeMD at Neutral With $7 Price Target	MT
09/11/24	B. Riley Adjusts Price Target on LifeMD to $12 From $11, Maintains Buy Rating	MT
08/08/24	B. Riley Trims Price Target on LifeMD to $11 From $12, Maintains Buy Rating	MT
11/07/24	KeyBanc Adjusts Price Target on LifeMD to $10 From $12, Maintains Overweight Rating	MT
05/06/24	KeyBanc Initiates LifeMD at Overweight With $12 Price Target, Cites 'Strong Top & Bottom-Line Growth'	MT
10/05/24	Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating	MT
23/04/24	BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating	MT
13/03/24	Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	MT
13/03/24	Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating	MT
12/03/24	B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating	MT
12/01/24	HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating	MT
15/11/23	Cantor Fitzgerald Adjusts LifeMD's Price Target to $9 From $8, Maintains Overweight Rating	MT
10/11/23	HC Wainwright Adjusts Price Target on LifeMD to $10 From $9, Maintains Buy Rating	MT
10/11/23	B. Riley Raises LifeMD's Price Target to $11 From $7 After Q3 Topline Beat, Maintains Buy Rating	MT
03/10/23	Cantor Fitzerald Adjusts LifeMD Price Target to $8 From $7, Maintains Overweight Rating	MT
21/07/23	Cantor Fitzgerald Starts LifeMD at Overweight With $7 Price Target	MT
10/07/23	B. Riley Raises LifeMD's PT to $7 From $3.50 on Increased Conviction for Durable Growth, Enhanced EBITDA; Keeps Buy Rating	MT
03/07/23	HC Wainwright Initiates LifeMD With Buy Rating, $9 Price Target	MT
24/03/23	BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	MT

More recommendations

Medical Software & Technology Services

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
LIFEMD, INC.			+151.94%
VEEVA SYSTEMS INC.			+13.77%
PRO MEDICUS LIMITED			+22.29%
SECTRA AB			+20.23%
HEARTFLOW, INC.			-11.03%
GENERATE BIOMEDICINES, INC.			+55.35%
OMNICELL, INC.			+78.41%
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	-		+55.58%
ARBUTUS BIOPHARMA CORPORATION	-	-	+9.99%
Average			+44.06%
Weighted average by Cap.			+17.78%